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Background: Cognitive deficits are stable features of schizophrenia that are linked to functional outcome. Cognitive
remediation approaches have been proven successful in ameliorating these deficits, although effect sizes vary
considerably. Whether cognitive deficits are serious predictors of clinical outcome is less clear.
Methods: Sixty patients suffering from schizophrenia were included in our sample, thirty of them received
computer-assisted cognitive training, and thirty received occupational therapy. For a subsample of 55 patients, who
could be traced over a period of five years after the end of the cognitive remediation intervention, time until first
relapse and time in psychosis were determined retrospectively from their medical records.
Results: Cognitive remediation significantly improved problem solving, memory and attention with high effect
sizes. Employment status, a post test verbal memory performance measure and a measure of executive functioning
outperformed all other measures in the prediction of time to relapse, while allocation to treatment group
outperformed all other variables in the prediction of both cognitive measures.
Conclusions: Cognitive remediation of neurocognitive deficits thus makes sense in a twofold fashion: It enhances
cognition directly and positively acts on clinical course indirectly via improved neurocognition.
Trial registration: German Clinical Trials Register: DRKS00004880
Keywords: Schizophrenia, Cognition, Cognitive remediation, Outcome, Prediction, Clinical courseBackground
In the last decades there has been growing interest in
the topic of cognitive functioning in schizophrenia,
starting from initial hints that cognitive deficits might be
significant predictors of social and vocational function-
ing after (successful) treatment of psychotic symptoms.
A huge number of studies were conducted to answer
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reproduction in any medium, provided the orDo schizophrenia patients suffer from stable cognitive
deficits?
A substantial number of studies - as summarized in se-
veral meta-analyses [1-3] - report stable deficits in many
cognitive domains, such as attention, verbal and visual
(working-) memory and executive functions. High effect
sizes of 1.0 and above indicate robust impairments.
There is empirical evidence that cognitive impairment
can be also found before first onset [4] and in persons at
risk for schizophrenia (children, siblings, parents of
schizophrenia patients) [5,6] while there is currently
some debate about whether these cognitive deficits are
specific enough to serve as diagnostic criteria for schizo-
phrenia (see for example [7] vs. [8]).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic and clinical characteristics
Characteristic Experimental
group (n = 30)
Control group
(n = 30)
N % N %
Gender
Male 15 50.0 15 50.0
Female 15 50.0 15 50.0
Medication
Atypical antipsychotic 10 33.3 11 36.7
Typical antipsychotic 1 3.3 4 13.3
Both 19 63.3 15 50.0
Partnership 12 40 8 26.7
Employment status (working) 12 40 13 43.3
Housing in own apartment / house 19 63.3 20 66.7
Mean SD Mean SD
Age 36.43 12.99 36.87 14.65
Years of education 10.83 3.25 10.47 2.45
Duration of illness 7.93 8.28 8.97 9.65
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Many studies have analyzed functional consequences of
cognitive deficits and have found small to moderate
correlations with functional outcome [9-11]: Cognitive per-
formance seems to be linked to social skills, community
functioning, social behavior, social problem solving [12] and
even the probability of returning to work or school [13]
regardless of potential moderator variables such as age,
gender, inpatient status and illness chronicity. Even link-
ages to further clinical course of illness have been
reported by some authors [14-18], although predictive
power was limited and there are several studies that could
not find any significant relations with neurocognition [19-21].
Is it possible to remediate neurocognitive deficits?
Three recent meta-analyses considering a huge number of
patients have focused on the effects of cognitive remedi-
ation in schizophrenia [22-24] reporting effect sizes for
overall cognition of 0.38 to 0.45 with effect sizes of about
the same for follow-up assessments. Cognitive remedi-
ation seems to be more effective when combined with psy-
chiatric rehabilitation interventions and may boost the
effects of other remediation programs. The authors agree
in their estimation that the effect sizes are rather un-
affected by age of the participants, use of computers, fre-
quency and duration of training as well as type of control
condition (active or treatment as usual). However, when
cognitive remediation therapy is combined with adjunctive
psychiatric rehabilitation and when social functioning is
considered, strategy based training approaches appear to
be superior to pure ‘drill and practice’ approaches [25].
In a former trial [26] we assessed the effects of
computer-aided cognitive training using a very game-like
and motivating software [27] in forty outpatients suffering
from schizophrenia. Twenty of the participants received
cognitive training; twenty received occupational therapy
twice a week for ten weeks. Enhancing effects on executive
functioning level and verbal memory as well as effects on
positive and negative symptom levels could be found.
Studies linking cognitive remediation and long-term
clinical course of schizophrenia are rare.
The present study describes effects of a cognitive re-
mediation intervention using the same cognitive training
software on cognitive performance of 60 schizophrenia
inpatients and implications for their further clinical
course over a period of 5 years. We hypothesized that
our intervention has a strong effect on cognitive per-




Sixty inpatients of the psychiatric hospital in Bamberg,
Germany were included. All of them fulfilled the Inter-national Classification of Diseases-10 (ICD-10), as well
as the Diagnostic and Statistical Manual of Mental
Disorders-IV (DSM-IV) criteria for schizophrenia and
were diagnosed based on the Structured Clinical Inter-
view for the DSM-IV (SCID) [28] performed by physi-
cians blind to treatment allocation. After a complete
description of the study, written informed consent was
obtained from all subjects. The study adhered to the
principles of Good Clinical Practice of the International
Conference on Harmonization and the Declaration of
Helsinki and was approved by the local ethics board
(University of Bamberg).
Thirty patients were included in the experimental
group (EG) and thirty patients matched by gender, age
and educational level formed the control group (CG).
Clinical and demographic characteristics of all partici-
pants are described in Table 1.
The experimental group received four 60-minute
training sessions per week for three weeks during their
stay at the psychiatric ward (twelve sessions in total)
using the “game-like” cognitive training software X-Cog®,
that was explicitly designed to motivate patients as much
as possible while “playing” the tasks (for more details see
[26]). The version administered to the patients consisted
of sixteen visuomotor, memory, problem-solving and
attention tasks. Participants had to control characters
that face several adventurous challenges, such as rescu-
ing a princess which has been captured inside of a maze,
protecting salads from hungry snails etc. Each task can
be administered in five different levels of difficulty from
‘beginner’ to ‘superprofessional’. Every time a specified
level for each task is mastered successfully completed,
this is indicated by the software, and the participants
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sents screen shots and short descriptions for some se-
lected tasks; a free trial version of the software can be
downloaded at www.x-cog.de/xcogen.html.
In small groups of three to four patients, 16 tasks that
target attention, verbal and visuospatial memory as well
as problem solving skills were administered by either
one experienced psychologist or occupational therapist
who selected the appropriate (and increasing) degree of
difficulty based on the participants’ achievement level.
All participants completed all 12 training sessions.
Instead of cognitive remediation sessions, CG patients
received twelve sessions of occupational therapy (paint-
ing and handicraft). Participants were told that they will
receive cognitive training or occupational therapy to im-
prove their mental performance.
Additionally to cognitive remediation or occupational
therapy, all patients of both groups received anti-
psychotic drug therapy and periodic visits by a clinical
psychiatrist, most of the patients (70 to 80 Percent in
both groups) furthermore received sports therapy and
music therapy once a week. Furthermore a minority of
patients (30 to 40 percent in both groups) attended re-
laxation therapy groups (twice a week) and received
CBT sessions guided by a psychologist (once a week).Figure 1 Screen shots and descriptions of some selected tasks in X-CAfter their inpatient stay, those patients that could be
traced had regular brief (ten to twenty minutes) appoint-
ments with their attending psychiatrist about once per
month. Both groups did not differ with respect to the
frequency of these other therapeutic interventions. Par-
ticipants were recruited and assigned to either experi-
mental or control group alternatively in two blocks of 15
patients each in order to blind EG participants to the
treatment of the CG and vice versa. Symptom levels
were obtained before and after treatment for all patients
using German versions of the Scale for the Assessment
of Positive Symptoms (SAPS) [29], the Scale for the As-
sessment of Negative Symptoms (SANS) [30] both rated
by a senior psychiatrist who was blind to treatment allo-
cation and the Paranoid-Depression Scale (PD-S) self-
rating-scale [31]. Inter-rater reliability was not assessed.
Cognitive functioning was assessed using the Wisconsin
Card Sorting Test (WCST) [32], the German version of
the Wechsler Memory Scale (WMS-R) [33], the Trail
Making Test (TMT) Part A und B [34] and two versions
of the Continuous Performance Test (CPT) for the assess-
ment of sustained attention: The degraded CPT [35] and
the 3–7 CPT [36]: In the degraded version, participants
had to respond to a target blurred digit ′3′ in a
pseudorandomized sequence of blurred digits, while in theog.
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lows a ′3′.
Our sample size provides 85% power to detect an im-
provement of 30 percent in the WCST ‘total errors’
measure for the experimental group compared to the
control group for a two study groups design using a con-
tinuous primary endpoint [37] when the estimated
standard deviation was taken from the former cognitive
remediation study described above.
Five years after end of treatment, time until rehospita-
lisation (if any) for those patients, who could be traced
(28 patients from the EG, 27 patients from the control
group) was assessed retrospectively from the medical
records of attending physicians / psychiatric hospitals.
Each inpatient stay of at least three consecutive days
during the follow-up period was considered a rehospi-
talisation. In fact, the minimum duration of stay found
in our sample was 5 days, so every inpatient stay for all
of our participants was included in the analyses.
Additionally total time in psychosis was obtained as a
measure of treatment intensity by adding the days of all
inpatient stays during the follow up period.
Data analysis
In a first step, t-tests for independent samples and
chi-square tests were performed to evaluate differences
in CG and EG at pre-test time.
Then, to avoid multiple testing, multivariate analyses
of variance were computed using treatment group
(EG vs. CG) as group factor, “time” (pretest at day 1 vs.
posttest at day 14) as repeated measures factor and the
following (groups of) dependent variables:
 Attention (degraded and 3–7 CPT measures)
 problem solving (WCST measures and TMT B
minus TMT A processing time)
 memory (WMS scores),
 processing speed (TMT A and B processing time),
 positive symptoms (SAPS subscales),
 negative symptoms (SANS subscales) and
 self-rating scores of depressive and paranoid
symptoms (PD-S subscales).
For those multivariate analyses that showed significant
(p < 0.05) interaction effects ‘group x time’ and thus indi-
cated differential effects of cognitive training, univariate
ANOVAS for each dependent variable were performed.
Parts of these results for a subset of the neurocognitive
measures collected have already been published else-
where [38].
A Cox regression survival analysis was performed to
figure out measures that may predict time until patients’
next relapse. Information about the patient’s clinical
and demographical data (partnership, years of education,post-treatment employment status, time since onset of
illness and habitation status, medication, gender, age) as
well as cognitive achievement level and symptom level
at pre and posttest were introduced as independent
variables in a stepwise procedure. Based on their
standardized regression weights Odds-Ratio values were
computed for those variables included in the equation.
To figure out possible predictors of patients’ time in
psychosis a linear stepwise regression analysis was
performed using time in psychosis as dependent variable
and the same set of variables as for the Cox regression
described above as predictors.
Since posttest WMS-R verbal memory performance
and WCST perseveration errors were the only cognitive
variables that significantly predicted time until relapse
and time in psychosis, two stepwise linear regression
analyses were performed using either verbal memory
scores or WCST perseveration errors at posttest as
dependent variable in order to search for possible pre-
dictors of both cognitive measures. All baseline mea-
sures, including “allocation to treatment group” (EG vs.
CG) were included as independent variables.Results
Clinical and demographic characteristics as well as
neurocognitive measures of all participants are described
in Tables 1 ,2 and 3 - the groups did not differ in any of
the measures shown (t-values between .01 and 1.39, n.s.;
χ2 for medication, housing, partnership and working:
2.32, .73, 1.20, .69, n.s.) except for the total number of
WCST errors where EG patients showed a trend to-
wards higher scores (t = 1.99, p = .053).
Results of multivariate and univariate ANOVAS for
neurocognitive measures are shown in Table 2. As can be
seen, significant multivariate interaction effects could be
found for attention, memory and problem solving mea-
sures while no differential changes for EG and CG from
pre to posttest could be found for processing speed.
Univariate analyses revealed significant interaction
effects for degraded CPT commission, 3–7 CPT omis-
sions as well as all problem solving and memory mea-
sures. Inspection of mean values shows an improvement
of performance only for EG patients while achievement
measures appear unchanged for CG patients.
The corresponding results for symptom measures are
displayed in Table 3. Only SAPS and PD-S scales show
significant multivariate interaction effects. Univariate
analyses point to stronger decreases in SAPS ‘delusions’
as well as in self-rated ‘paranoid’ and ‘depressive’ symp-
toms for EG patients.
Mean time until first relapse for those participants
experiencing any relapse was 526.6 days (SD = 425.8,
n = 20) for the experimental and 390.1 days (SD = 433.0,
Table 2 Mean values and results of repeated measures analyses of variance: neurocognitive measures
EG (n = 30) CG (n = 30) Main effect Main effect Interaction
Pretest Posttest Pretest Posttest “group” “time” “time x group”













Attention (multivariate) .578 .680 5.266 .001 4.606 .003
Degraded CPT omissions 15.48 (14.45) 10.54 (10.99) 15.44 (14.60) 13.92 (12.77) .029 .866 5.830 .019 1.639 .206
Degraded CPT comissions 2.59 (2.28) 1.03 (1.49) 1.85 (1.95) 1.98 (3.45) .038 .847 6.086 .017 8.561 .005
3-7 CPT omissions 26.05 (16.24) 18.70 (13.34) 23.80 (14.23) 24.07 (16.85) .205 .652 3.537 .065 4.104 .047
3-7CPT comissions 1.68 (1.71) 0.89 (0.92) 1.87 (2.14) 1.81 (2.35) 1.562 .216 4.971 .030 3.725 .059
Memory (multivariate) 1.557 .220 63.811 <.0005 51.214 <.0005




84.23 (24.58) 87.10 (21.63) 2.267 .138 47.757 <.0005 26.993 <.0005




83.57 (16.44) 83.27 (18.73) 2.597 .112 48.653 <.0005 51.170 <.0005
Problem solving (multivariate) 1.694 .179 7.895 <.0005 20.416 <.0005
WCST % total errors 28.69 (3.84) 19.94 (3.45) 25.23 (8.71) 27.78 (7.90) 2.188 .145 17.427 <.0005 57.793 <.0005
WCST % failure to maintain set 6.79 (3.80) 3.28 (2.12) 5.66 (4.29) 6.47 (4.82) 1.263 .266 10.590 .002 26.918 <.0005
WCST % perseveration errors 9.11 (4.45) 2.87 (2.22) 7.53 (5.42) 8.74 (6.45) 3.920 .052 15.192 <.0005 33.180 <.0005
TMT B-A 80,53 (48,93) 53.13 (23.65) 88.13 (56.80) 77.47 (49.42) 2.147 .148 14.513 <.0005 2.804 .046
Speed of processing 1.120 .333 11.489 <.0005 2.026 .141
TMT A performance time 49.43 (20.21) 40.77 (16.49) 49.90 (20.27) 46.20 (15.19)






Table 3 Mean values and results of repeated measures analyses of variance: symptom measures
EG (n = 30) CG (n = 30) Main effect Main effect Interaction
Pretest Posttest Pretest Posttest “group” “time” “time x group”
Measure mean (SD) mean (SD) mean (SD) mean (SD) F(4/55) mv. p F(2/57) mv. p F(2/57) mv. p
F(1/58) uv. F(1/58) uv. F(1/58) uv.
SAPS scales (multivariate) 1.372 .256 36.896 <.0005 4.475 .003
hallucinations 1.48 (.82) .22 (.50) 1.72 (1.00) .76 (.89) 4.210 .045 126.744 <.0005 2.433 .124
delusions 1.85 (.82) .44 (.41) 1.79 (.93) 1.15 (.76) 3.573 .064 116.570 <.0005 16.464 <.0005
Bizarre behavior .85 (.73) .29 (.39) .61 (.70) .49 (.49) .243 .624 17.415 <.0005 3.635 .062
positive formal thought disorder .98 (1.08) .48 (.68) .91 (.82) .52 (.49) .002 .963 18.452 <.0005 .282 .598
SANS scales (multivariate) 1.611 .173 8.128 <.0005 .631 .677
Affective flattening or blunting 1.43 (1.35) .87 (.83) 1.93 (1.44) 1.25 (1.09)
alogia 1.45 (.85) .82 (.91) 1.74 (1.21) 1.38 (1.19)
Avolition / apathy 1.18 (1.37) .76 (1.30) 1.30 (1.47) 1.01 (.98)
Anhedonia / asociality 1.49 (1.26) .58 (.96) 1.88 (1.24) 1.26 (1.09)
attention 1.13 (1.26) .53 (1.21) 1.45 (1.27) .75 (.85)
PD-S scales (multivariate) 2.293 .110 12.812 <.0005 3.405 .040
Paranoid thinking 94.06 (8.90) 78.56 (22.02) 95.53 (7.12) 89.65 (15.05) 4.665 .035 20.519 <.0005 4.160 .046
Depression 85.83 (16.97) 68.93 (24.53) 83.81 (28.92) 79.64 (26.19) .587 .447 13.749 <.0005 5.017 .029
Trapp et al. BMC Psychiatry 2013, 13:184 Page 5 of 9
http://www.biomedcentral.com/1471-244X/13/184
Trapp et al. BMC Psychiatry 2013, 13:184 Page 6 of 9
http://www.biomedcentral.com/1471-244X/13/184n = 19) for the control group. This difference does not
reach statistical significance (t(37) = .99, n.s.).
The stepwise procedure in the Cox Regression analysis
used to predict time to relapse stopped when two vari-
ables – employment status (currently in education or
working paid or unpaid in a part- or full-time job vs. un-
employed; Wald statistic = 6.54, p = .011, Odds-Ratio =
1/exp(B) = 2.54) and verbal memory score at posttest
(Wald statistic = 4.97, p = .026, Odds-Ratio = 1/exp(B) =
2.15) - were included in the equation. Figure 2 shows
separate Kaplan Meier survival plots for both variables.
Only three predictors: verbal (beta = .609, p < .0005)
and visual memory (beta = .236, p = .007) at baseline as
well as “treatment” (beta = .466, p < .0005) remained in
the stepwise linear regression procedure’s equation
(R2 = .739) using post test verbal memory performance
as dependent variable.
Average values for time in psychosis for those partici-
pants experiencing any relapse was shorter for the
cognitive remediation group (mean = 75.0, SD = 51.0)
than for the control group (mean = 140.4, SD = 123.6,
t(37) = 2.14, p = .043, Cohen’s d = .58). When time in
psychosis and number of rehospitalisations is analyzed
for the entire sample (with time in psychosis scored 0
for those patients without relapse) differences between
both groups do not reach a two-sided α < .05 level (mean
values: 53.6(55.0) vs. 100.9(120.5), t(53) = 1.86, p = .071,
Cohen’s d = .43).
In contrast to the results of the Cox regression for
time until relapse, the stepwise linear regression proced-
ure to predict time in psychosis resulted in an equation
containing only one WCST variable for the entire sam-
ple (post-intervention perseveration errors, beta = .292,
p = .031, R2 = .085). Two predictors: WCST total errors
(beta = .427, p < .0005) at baseline and “treatment”Figure 2 Kaplan Meier survival plots for employment status and verb(beta = .625, p < .0005) remained in the stepwise linear
regression procedure’s equation (R2 = .409) using post-
intervention WCST perseveration errors as dependent
variable.
Figure 3 summarizes all parameters that directly or in-
directly predict time until relapse and time in psychosis
in our sample.
Discussion
This study highlights positive effects of computer-aided
cognitive training. We found independent general effects
on participants’ memory, attention and executive per-
formance. When time to relapse and time in psychosis
five years after the cognitive remediation intervention
was analyzed in further detail, verbal memory and prob-
lem solving performance at posttest as well as employ-
ment status turned out to be the most economic
predictors in a stepwise regression procedure. Surely, it
is easier to influence cognitive performance during a few
weeks inpatient stay and in our sample - even when all
other potential influential factors assessed were taken
into account – post-intervention cognitive achievement
level seems to be solely influenced by performance level
before training and training itself.
Cognitive remediation effect sizes
In our sample effects of CRT on nearly all cognitive do-
mains assessed with effect sizes ranging from medium to
high levels (Cohen’s d values range from 0.35 for atten-
tion measures to 1.29 for WCST errors, see Table 4)
could be found.
The finding that relatively small effect sizes for atten-
tion were obtained corresponds with the results of two
recent meta analyses investigating the effects of CRT
[22,24]: The authors report similar Cohen’s d values ofal memory performance at posttest.
Figure 3 Measures predicting days until relapse and time in psychosis.
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and .57 for problem solving, .37 and .41 for verbal
and -.08 and .15 for visual memory compared to our
findings. Visuospatial memory was not assessed in our
outpatient study for it was not subject to training in
contrast to the present contribution. And surprisingly
the effect size is very high compared to an overall non-
significant effect in the collected data of the recent re-
views. Unfortunately the authors did not report which
cognitive domains were addressed by cognitive remedi-
ation, so their findings may be partly due to the fact that
nonverbal memory was not subject to cognitive training
in many cases.
It is of course difficult to judge why the effect sizes for
problem-solving and memory measures are higher in
our two samples. One could argue, that the positive
effects are just an incidental finding, although they were
found in two independent samples comprising 100 pa-




Degraded CPT comissions .36
3-7 CPT omissions .35
Memory
WMS composite score “verbal memory” .85
WMS composite score “visual memory” 1.13
Problem solving
WCST % total errors 1.29
WCST % failure to maintain set .86
WCST % perseveration errors 1.22
TMT B-A .63One other obvious explanation could be that quality of
both studies with respect to allocation to treatment is low
(no randomization). But, as could be found recently, inde-
pendent randomization seems to have no effect on the ex-
tent of the effects of cognitive remediation therapy [22].
Neurocognition and clinical course
As already stated in the ‘introduction’ section, cognitive
impairment appears to be a stable feature in schizo-
phrenic patients: It seems to be hardly affected by
pharmacological antipsychotic treatment, tends to be
stable over time and is present before and at onset of
psychosis. Furthermore, there is broad empirical data,
that cognitive deficits are linked to functional outcome,
and that particular cognitive impairments may even
serve as predictors of specific domains of functional out-
come [12,39-41]. It is still unclear whether cognitive
functioning is related to clinical outcome. By now, only
very few studies examined associations of neurocognitive
performance to measures like ‘time in psychosis’ or ‘time
to first relapse’. Unfortunately, those that discovered
significant relationships considered shorter follow-up
intervals and, maybe because of this, utilized weaker
measures like ‘clinical deterioration’ as criterion for clin-
ical outcome. The probability to get significant correla-
tions of cognitive measures with clinical outcome may of
course be higher when they are based on a shorter
follow-up period.
Our finding that verbal memory performance and a
measure of executive functioning predict time to first re-
lapse and time in psychosis partly matches with results
of former studies linking neurocognitive measures to
clinical outcome.
Like in our sample, of those studies that revealed sig-
nificant relationships between cognitive measures and
clinical course two [15,18] found significant relationships
Trapp et al. BMC Psychiatry 2013, 13:184 Page 8 of 9
http://www.biomedcentral.com/1471-244X/13/184with verbal memory (although it has to be admitted that
in [15] only self rating of memory performance was
assessed). Two other studies did not assess verbal mem-
ory ([14,16], in [14] verbal learning instead of delayed
verbal memory was assessed) and in the remaining con-
tribution [17] TMT-B score, a measure also focusing on
cognitive flexibility similar to WCST perseveration er-
rors score outperformed all other measures.
When transition to psychosis is used as a criterion for
high-risk samples, verbal memory also repeatedly has
been found to be the best predictor [42-44].
There are various possibilities, how cognitive impair-
ment may influence further clinical course: On the one
hand, as cognitive impairment is linked to poor func-
tional outcome, insufficient functioning resources may
in turn lead to higher stress levels resulting from insuffi-
cient coping with life-events and daily hassles. Psycho-
social stress is considered a major risk factor for relapse
of psychotic symptoms [45-47]. On the other hand good
cognitive achievement levels may support treatment
compliance and especially may prevent patients from
forgetting to take their antipsychotic medication, or
from missing appointments with their psychiatrists /
consultants [48-50].
Cognitive training itself did not predict time to relapse
and only a weak linkage to time in psychosis was found
for the entire sample reaching statistical significance
only on a one-sided α < .05 level. This is not too surpris-
ing because cognitive achievement level of course is not
only dependent from cognitive remediation interven-
tions but from other factors like baseline achievement
level also. However, in our sample cognitive remediation
significantly affected cognitive achievement level even
when baseline performance was controlled and therefore
may have acted indirectly on further course of illness.
Limitations and implications for future research
Despite of encouraging results, our sample size of sixty
patients is rather small compared to those of other stud-
ies examining the effects of CRT, which leads to weaker
statistical power and makes it harder to generalize our
findings.
Our finding that employment status was only linked to
time until rehospitalisation might be due to the fact that
only post-intervention employment status was assessed.
It is likely that changes in employment level may have
occurred and that these changes might have interacted
with clinical outcome. Unfortunately we did not collect
any data to verify this hypothesis.
Since relapse was determined retrospectively, milder
forms of relapse prior to rehospitalisation remained un-
detected and thus were not included in the analyses.
Unfortunately, our participants were not allocated to
treatment in a randomized fashion. This clearly reducesmethodological quality and therefore at least the results
of the cognitive training intervention should be regarded
as preliminary, although, as stated above in this section,
current empirical evidence seems to indicate that non-
randomized allocation does not influence effect sizes of
cognitive training interventions.
Conclusion
This study provides preliminary evidence that cognitive
training may be able to indirectly influence the long-term
course of illness in schizophrenic patients: Two cognitive
measures and a vocational variable outperformed all other
variables as predictors. While it may be difficult to change
patients’ employment status during an inpatient stay in a
psychiatric hospital, cognitive training could be a powerful
instrument to boost cognition and by this means indirectly
improve further course of illness.
This is of particular importance considering the chronic
and disabling nature of this severe disease starting in
early life.
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